<DOC>
	<DOC>NCT00354510</DOC>
	<brief_summary>The purpose of this study is to investigate the clinical efficacy of 3% (w/w) GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI) assessment of disease severity and to investigate the safety of and tolerability of 3% GW842470X cream on diseased skin of adult patients.</brief_summary>
	<brief_title>Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Inclusion criteria: Moderate atopic dermatitis patients (IGA=3). The disease involvement must be &gt;5% of body surface area. Female patients of childbearing potential must use an appropriate method of contraception. Exclusion criteria: Patients with any active skin disease other than atopic dermatitis will not be eligible. Patients who have had systemic treatment for atopic dermatitis or other topical or transdermal treatments (such as nicotine, hormone replacement therapies) within 14 days prior to first application of study medication and/or topical treatment with tar, any corticosteroid, topical immunomodulators or oral treatment with any corticosteroids within 10 days prior to first application and/or oral antihistamines within 5 days of the first dose.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>GW842470X</keyword>
	<keyword>PDE4 inhibitor</keyword>
</DOC>